UBS Group’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

UBS Group’s Portfolio CMTA Stock Details CMTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,918	Closed	-$128K	–	8482
2019 Q1	$128K	Buy	+4,918	New	+$91.9K	﹤0.01%	4906
2018 Q2	–	Sell	-908	Closed	-$14K	–	8459
2018 Q1	$14K	Buy	908 +183	+25%	+$2.98K	﹤0.01%	6690
2017 Q4	$13K	Buy	725 +567	+359%	+$9.49K	﹤0.01%	6890
2017 Q3	$3K	Buy	+158	New	+$2.58K	﹤0.01%	7428

UBS Group's CMTA Position: Q2 2019 in Review

UBS Group sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2019, closing a stake of 4,918 shares — an estimated $128K sold.

UBS Group first reported a position in CMTA in Q3 2017 and held it in 4 quarters. The position peaked at $128K in Q1 2019. 0 funds tracked by Wall St. Rank hold CMTA as of Q2 2019.

UBS Group reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
UBS Group sold 4,918 Clementia Pharmaceuticals Inc. shares in Q2 2019, an estimated $128K.
UBS Group first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 4 quarters.
UBS Group's Clementia Pharmaceuticals Inc. position peaked at $128K in Q1 2019.
0 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2019.

Based on UBS Group's 13F filing for Q2 2019, filed 14 Aug 2019.